Update on current animal models for schizophrenia: are they still useful?. Issue 3 (25th May 2023)

• Record Type: Journal Article
• Authors: Uliana, Daniela L.; Gomes, Felipe V.; Grace, Anthony A.
• Is Part Of: Current opinion in psychiatry. Volume 36:Issue 3(2023)
• Page Start: 172
• Page End: 178
• Publication Date: 2023-05-25
• Subjects: animal models -- antipsychotics -- dopamine -- schizophrenia; Psychiatry -- Periodicals; 616.89005
• DOI: 10.1097/YCO.0000000000000854
• Languages: English
• ISSNs: 0951-7367

Abstract

Abstract : Purpose of review: Schizophrenia is a psychiatric disorder that has a significant socioeconomic impact worldwide. Antipsychotic drugs targeting dopamine transmission alleviate psychotic symptoms but with limited efficacy and tolerability. Animal models have long proven useful for drug discovery. The continued need for new treatment highlights the importance of animal models to study schizophrenia. The lack of new therapeutic compounds combined with the shortcomings of clinical design studies potentially decreased the enthusiasm for animal model use. Recent findings: In the current review, we discuss the central role of animal models for schizophrenia in providing new insights into neurobiological features and therapeutic development. The US National Institute of Mental Health released the Research Domain Criteria to guide preclinical model studies. Here, we point out the advances of this approach and debate its potential limitations when using animal models to study schizophrenia from the drug discovery perspective. Summary: Cross-validated animal models for schizophrenia are crucial to comprehend the cause, pathophysiology, and behavioral and biological features of the disease, to advance prevention and treatment, and the need to carefully evaluate and select appropriate paradigms when investigating novel therapeutic targets.